Forecast

Financial forecast

Project revenue, EBITDA, net income and free cash flow for the next 5 or 10 years. Growth starts at the same rate the valuation uses and fades to the long-run rate, with margins held at today's level. Bear and bull cases move growth by the company's own revenue volatility. It is a model of what the assumptions imply, not a prediction.

Zealand Pharma A/S (ZEAL.CO)

Price updated 06 Nov 2026 09:57; TTM through 30 Jun 2026; TTM financials updated 06 Nov 2026 14:03.

Starts from TTM through 30 Jun 2026 financials in DKK and a share price of DKK 235.70. Growth begins at 6.7% a year (the valuation's blended assumption) and fades to 2.9% by year 10. Margins held at EBITDA 56.8%, net 59.0%, free cash flow -38.7% of revenue. Bear and bull move starting growth by 6.0 points and long-run growth by 1 point.

Free cash flow is negative today, so the projection keeps it negative. It does not model a turnaround.
Year 1 uses analyst consensus revenue growth (-11.6%); year 2 is halfway back to the model's own path.
DKK 366.75Model fair value (Earnings-based DCF); range DKK 275.07 to DKK 526.26
56%Fair value vs today's price
LowModel confidence
25%Share of the gap to fair value the price closes by year 5

Confidence: EV/EBITDA (12x) is somewhat apart; trailing-twelve-month data; free cash flow is negative, so the earnings may not be turning into cash.

3.3%/yrModel-implied annual total return over 10 years, base case (price plus dividends). Raw model level; the screener shows a calibrated ranking instead
DKK 5.63BRevenue in year 10 (base)
DKK 3.32BNet income in year 10 (base)
-DKK 2.18BFree cash flow in year 10 (base)
DKK 325.23Implied share price in year 10 (base), today DKK 235.70
-13.0%Year-10 free cash flow per share vs today's price

Net income over time

-DKK 1.20B DKK 712.15M DKK 2.63B DKK 4.54B DKK 6.46B FY2022 FY2023 FY2024 FY2025 TTM through 30 Jun 2026 +1 +2 +3 +4 +5 +6 +7 +8 +9 +10
Solid: reported Dashed: base projection Shaded: bear to bull range
Net income in year 10 by scenario
CaseStarting growthYear 10Annual growth
Bear -17.6% DKK 2.32B -1.7%
Base -11.6% DKK 3.32B 1.9%
Bull -5.6% DKK 4.68B 5.5%

Base case by year

YearGrowthRevenueEBITDANet incomeFree cash flowEPSFCF / shareDividend / shareBook / shareImplied price
TTM through 30 Jun 2026– DKK 4.64BDKK 2.64BDKK 2.74B-DKK 1.80B 38.71-25.39n/an/a235.70
Year 1-11.6% DKK 4.10BDKK 2.33BDKK 2.42B-DKK 1.59B 34.21-22.44n/an/a214.10
Year 2-2.7% DKK 3.99BDKK 2.27BDKK 2.36B-DKK 1.55B 33.29-21.84n/an/a214.02
Year 35.9% DKK 4.23BDKK 2.40BDKK 2.49B-DKK 1.64B 35.24-23.12n/an/a232.52
Year 45.4% DKK 4.46BDKK 2.53BDKK 2.63B-DKK 1.73B 37.16-24.37n/an/a251.44
Year 55.0% DKK 4.68BDKK 2.66BDKK 2.76B-DKK 1.81B 39.02-25.60n/an/a270.65
Year 64.6% DKK 4.90BDKK 2.78BDKK 2.89B-DKK 1.89B 40.81-26.77n/an/a283.07
Year 74.2% DKK 5.10BDKK 2.90BDKK 3.01B-DKK 1.97B 42.51-27.89n/an/a294.86
Year 83.7% DKK 5.29BDKK 3.00BDKK 3.12B-DKK 2.05B 44.10-28.93n/an/a305.90
Year 93.3% DKK 5.47BDKK 3.10BDKK 3.23B-DKK 2.12B 45.57-29.89n/an/a316.07
Year 102.9% DKK 5.63BDKK 3.19BDKK 3.32B-DKK 2.18B 46.89-30.76n/an/a325.23

EPS and free cash flow per share assume today's share count. Dividends assume today's payout ratio and book value grows with retained earnings. The implied share price follows the valuation models and is not a price target; override growth settings do not change the model fair value. Margins stay at today's level except where the notes say they drift toward their average, so it does not model margin expansion, buybacks, acquisitions or recessions. It is for information and education only and is not investment advice. See the methodology for how the growth rate is blended.